{
    "2020-10-09": [
        [
            {
                "time": "",
                "original_text": "北上资金全透视月报：上月外资大幅流出 加仓周期减持消费 减持股份",
                "features": {
                    "keywords": [
                        "北上资金",
                        "外资流出",
                        "加仓周期",
                        "减持消费"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【异动股】泰格医药(03347-HK)涨3.9%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "股价上涨"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "港股异动︱泰格医药(03347)涨超4% 获瑞银首予“买入”并预期今年收入可同比增13%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "股价上涨",
                        "瑞银",
                        "买入评级",
                        "收入增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业月报：医药板块调整或近尾声",
                "features": {
                    "keywords": [
                        "医药生物",
                        "板块调整",
                        "尾声"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "瑞银：预期今年收入同比增13% 首予泰格医药(03347)“买入”评级",
                "features": {
                    "keywords": [
                        "瑞银",
                        "收入增长",
                        "泰格医药",
                        "买入评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "瑞银：首予泰格医药“买入”评级，目标价149港元",
                "features": {
                    "keywords": [
                        "瑞银",
                        "买入评级",
                        "泰格医药",
                        "目标价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "瑞银：首予泰格医药(3347.HK)“买入”评级目标价149港元",
                "features": {
                    "keywords": [
                        "瑞银",
                        "买入评级",
                        "泰格医药",
                        "目标价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}